Skip to main content
Aurobindo Pharma Limited (NSE:AUROPHARMA)
India flag India · Delayed Price · Currency is INR
1,807.20
-20.30 (-1.11%)
Nov 12, 2026, 3:29 PM IST

Aurobindo Pharma Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
39,90235,04834,85931,73019,27526,482
Depreciation & Amortization
18,92417,09315,21214,39411,96210,833
Other Amortization
513.5513.5699.6525.2413.1432.4
Loss (Gain) From Sale of Assets
-9724389.4-234.9-132.31,558
Asset Writedown & Restructuring Costs
477493696.4623.7309.9-396.3
Loss (Gain) From Sale of Investments
-78.9-14.2-367-1--264.3
Loss (Gain) on Equity Investments
65.3-15.2316.9171.5116.7312.5
Provision & Write-off of Bad Debts
58.3132.6188232.8524.5-61.1
Other Operating Activities
-316.3131.2-3.5-6,3452,348-4,309
Change in Accounts Receivable
-11,064-11,707-8,621-2,642-4,321-4,108
Change in Inventory
-12,260-14,998-7,355-13,037-9,26714,975
Change in Accounts Payable
8,61012,816-3,1095,8287,0771,107
Change in Other Net Operating Assets
14,51115,5296,640-6,900-4,4383,605
Operating Cash Flow
59,24555,26439,24624,34523,86850,165
Operating Cash Flow Growth
-3.78%40.81%61.21%2.00%-52.42%50.69%

Investing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-27,527-26,858-19,679-27,803-24,038-20,529
Sale of Property, Plant & Equipment
941.1462.528.4602.8110.93,809
Cash Acquisitions
-23,171-3,032-113.9--1,970-5,814
Divestitures
-----43.2
Sale (Purchase) of Intangibles
-4,304-4,189-5,517-7,812-3,166-6,517
Investment in Securities
-784.1-7,819881.61,5354,428-3,361
Other Investing Activities
5,4726,8495,641-9,082-15,142252.6
Investing Cash Flow
-49,374-34,586-18,758-42,560-39,778-32,116

Financing Activities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Short-Term Debt Issued
-3,59220,611-20,697-
Long-Term Debt Issued
-3,6076,61415,6323,936827.3
Total Debt Issued
15,0237,19927,22615,63224,633827.3
Short-Term Debt Repaid
----847.6--26,367
Long-Term Debt Repaid
--14,125-12,287-1,638-981.2-1,331
Lease Payments
-2,039-1,085-1,098-1,466-924.7-1,331
Total Debt Repaid
-12,813-14,125-12,287-2,485-981.2-27,698
Net Debt Issued (Repaid)
2,210-6,92714,93913,14723,651-26,871
Repurchase of Common Stock
-8,058--9,302---
Common Dividends Paid
-2.5-2,324-10.4-2,636-4,395-2,637
Other Financing Activities
-3,371-3,441-4,428-2,507-1,112-185
Financing Cash Flow
-9,222-12,6921,1988,00418,144-29,693

Net Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
8,5508,28891141.7-0.62
Miscellaneous Cash Flow Adjustments
1.81.86.6-64.1-32.5
Net Cash Flow
9,20016,27621,784-10,0682,298-11,674

Free Cash Flow

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
31,71728,40619,568-3,458-170.529,636
Free Cash Flow Growth
-12.46%45.17%---56.71%
Free Cash Flow Margin
8.59%8.44%6.17%-1.19%-0.07%12.63%
Free Cash Flow Per Share
54.8748.9133.57-5.90-0.2950.58
Levered Free Cash Flow
12,12113,56011,575-12,590-4,80312,129
Unlevered Free Cash Flow
14,39115,76214,327-10,914-3,99712,359
Free Cash Flow After Leases
29,67827,32118,469-4,924-1,09528,304

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
3,4613,4414,2032,5071,112185
Cash Income Tax Paid
16,23618,32017,31417,6667,17212,582
Change in Working Capital
-203.21,639-12,445-16,751-10,95015,578